Unité de Fabrication des Médicaments S.A (BVMT:UMED)

Market Cap	300.80M
Revenue (ttm)	147.68M
Net Income (ttm)	19.37M
Shares Out	32.00M
EPS (ttm)	0.61
PE Ratio	15.53
Forward PE	14.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,918
Average Volume	51,395
Open	9.55
Previous Close	9.53
Day's Range	9.30 - 9.60
52-Week Range	6.83 - 9.60
Beta	0.03
RSI	69.13
Earnings Date	Sep 16, 2025

About BVMT:UMED

Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company offers Opthalmic, ENT, and inhalation solutions, infusion solutions, injectable fluids and penicillin, and cephalosporin powders, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It manufactures medicines for third party laboratories principals. Unité de Fabrication des Médicaments S.A. was founded in 1989 and is based in So...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 572
• Stock Exchange: Tunis Stock Exchange
• Ticker Symbol: UMED

Financial Performance

In 2024, BVMT:UMED's revenue was 147.68 million, an increase of 8.58% compared to the previous year's 136.00 million. Earnings were 19.37 million, an increase of 249.30%.